2015-11-05T09:37:47-06:00 2014-12-31 611436956 NOVAK FRANCELLA LLC ONE PRESIDENTIAL BLVD SUITE 330 BALA CYNWYD PA 19004 990 2014-01-01 412161648 INNOVATIONS IN CANCER THERAPY INNO 2023671164 2025 M STREET NW NO 800 WASHINGTON DC 20036 JEANNE MENDELSON EXECUTIVE DIRECTOR 2023671164 2015-11-05 1 LOUIS VERZELLA CPA P00360279 6106689400 2015-10-29 2014 2016-04-25 22:37:26Z JEANNE MENDELSON 2025 M STREET NW NO 800 WASHINGTON DC 20036 833772 0 X WWW.IO-CENTRAL.ORG X 2005 MA TO ESTABLISH,NURTURE AND SUPPORT INTERVENTIONAL ONCOLOGY AS THE FOURTH PILLAR OF CANCER THERAPY. 10 10 0 0 0 0 0 0 804199 832723 0 6 2241 1043 806440 833772 0 0 0 0 0 0 0 0 0 735044 962613 735044 962613 71396 -128841 361139 180313 71403 19418 289736 160895 TO ESTABLISH,NURTURE AND SUPPORT INTERVENTIONAL ONCOLOGY AS THE FOURTH PILLAR OF CANCER THERAPY. 0 0 ANNUAL MEETING - MULTIDISCIPLINARY SCIENTIFIC MEETING, WITH EXHIBITS, ON INTERVENTIONAL ONCOLOGY ISSUES. THE MEETING PRESENTS CURRENT INFORMATION ON RESEARCH, NEW PRODUCTS, AND NEW TECHNIQUES IN THE INTERVENTIONAL ONCOLOGY FIELD. 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 5 0 0 0 0 0 0 0 0 X 10 10 0 1 0 0 0 0 0 1 1 0 0 1 1 0 0 1 1 0 0 0 X SMITHBUCKLIN CORPORATION 2023671164 2025 M STREET SUITE 800 WASHINGTON DC 20036 X RICCARDO A LENCIONIMD CHAIR 2.00 X X 0 0 0 DAVID LUMD DIRECTOR 1.00 X 0 0 0 LUIGI SOLBIATIMD DIRECTOR 1.00 X 0 0 0 JEFF H GESCHWINDMD DIRECTOR 1.00 X 0 0 0 STEPHEN SOLOMONMD DIRECTOR 1.00 X 0 0 0 RIAD SALEM MD DIRECTOR 1.00 X 0 0 0 AFSHIN GANGI MD DIRECTOR 1.00 X 0 0 0 MICHAEL C SOULENMD PAST CHAIR 1.00 X 0 0 0 WILLIAM RILLING DIRECTOR 2.00 X 0 0 0 NAHUM GOLDBERG DIRECTOR 1.00 X 0 0 0 JEANNE MENDELSON EXECUTIVE DIRECTOR 8.00 X 0 0 0 0 0 0 0 0 0 0 SMITHBUCKLIN INC 2025 M STREET NW STE 800 WASHINGTON DC 20036 MANAGEMENT 298494 1 ANNUAL MEETING 900099 750275 750275 CORPORATE PARTNER PROG 900099 62448 62448 INTERNATIONAL MEETING 900099 10000 10000 PUBLICATION 900099 10000 10000 832723 6 6 MISCELLANEOUS 900099 1043 1043 1043 833772 832723 0 1049 35000 14115 51344 35833 34230 15491 763554 EDUCATION 12967 MISCELLANOUS 79 962613 243912 97858 52000 0 9104 16500 56123 65955 361139 180313 11578 17248 59825 2170 71403 19418 X 0 0 0 0 289736 160895 289736 160895 361139 180313 -128841 0 X X 1 X 0 1 0 0 X PART X, LINE 2: ACCOUNTING PRINCIPLES GENERALLY ACCEPTED IN THE UNITED STATES OF AMERICA REQUIRE MANAGEMENT TO EVALUATE TAX POSITIONS TAKEN BY THE ORGANIZATION AND RECOGNIZE A TAX LIABILITY IF THE ORGANIZATION HAS TAKEN AN UNCERTAIN POSITION THAT, MORE LIKELY THAN NOT, WOULD NOT BE SUSTAINED UPON EXAMINATION BY THE U.S. FEDERAL, STATE, OR LOCAL TAXING AUTHORITIES. THE ORGANIZATION IS SUBJECT TO ROUTINE AUDITS BY TAXING JURISDICTIONS; HOWEVER, THERE ARE CURRENTLY NO AUDITS FOR ANY TAX PERIODS IN PROGRESS. TYPICALLY, TAX YEARS WILL REMAIN OPEN FOR THREE YEARS; HOWEVER, THIS MAY DIFFER DEPENDING UPON THE CIRCUMSTANCES OF THE ORGANIZATION. FORM 990, PART VI, SECTION A, LINE 3 SMITHBUCKLIN MAINTAINS THE BOOKS AND RECORDS OF THE ORGANIZATION AND PERFORMS OTHER MANANGEMENT AND ADMINISTRATIVE FUNCTIONS FOR WHICH IT IS COMPENSATED. FORM 990, PART VI, SECTION B, LINE 11 THE 990 IS REVIEWED BY THE STAFF OF THE MANAGEMENT COMPANY, INCLUDING THE EXECUTIVE DIRECTOR AND A COPY OF THE 990 IS PROVIDED TO THE BOARD PRIOR TO FILING. FORM 990, PART VI, SECTION C, LINE 19 GOVERNING DOCUMENTS, CONFLICTS OF INTEREST AND FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST AT OFFICE OF THE MANAGEMENT COMPANY. FORM 990, PART XII, LINE 2C: INNOVATIONS IN CANCER THERAPY GOVERNING BODY IS RESPONSIBLE FOR THE FINANCIAL STATEMENT REVIEW AND SELECTION OF THE INDEPENDENT ACCOUNTANT PERFORMING THE REVIEW.